Highlights

  • Wedbush kept its “Neutral” rating and raised the price target sharply to USD 10.00.
  • STRO shares rose 19.21% to USD 8.70 on December 3, 2025.
  • A 1-for-10 reverse stock split for Sutro Biopharma was implemented on December 3.

Wedbush restated its “Neutral” rating on Sutro Biopharma (NASDAQ:STRO) in a report released Tuesday. The brokerage increased its price target from USD 2.00 to USD 10.00. This rating comes amid mixed analyst opinions, with two Buy ratings, four Hold ratings, and two Sell ratings. The average analyst target price currently stands at USD 5.80.

Other brokers have also provided recent updates. Wall Street Zen downgraded STRO to a Sell on November 8. Wells Fargo reduced its price target from USD 4.00 to USD 3.00 and rated the stock as Equal Weight.

Recent Earnings and Financials
Sutro Biopharma reported quarterly earnings of (USD 0.67) per share, missing analyst expectations of (USD 0.42). The company recorded a negative net margin of 206.77% and a negative return on equity of 852.70%. Quarterly revenue was USD 9.69 million, slightly below the USD 10.14 million estimate. Analysts project a -2.92 EPS for the current fiscal year.

Insider and Institutional Activity
Director Connie Matsui purchased 50,000 shares in October at USD 0.80 per share. Overall, insiders bought 111,754 shares valued at USD 89,601 in the last quarter. Institutional ownership remains high at 96.99%, with firms like Acadian Asset Management and RA Capital Management increasing positions during the year.

Stock Performance and Trading Data
STRO shares closed at USD 8.70 on December 3, up 19.21% for the day. Earlier in the day, STRO opened at USD 7.75, with a high of USD 8.91 and a low of USD 7.15. The company’s market capitalisation stands at USD 74.05 crore. Over the past 52 weeks, the share price has ranged from a low of USD 5.23 to a high of USD 30.10.